Clinical trial
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
NCT00082888 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00082888 |
|---|---|
| Title | Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma |
| Official title | Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma and 3 more |
| Intervention type | Drug, Other |
| Interventions | Laboratory Biomarker Analysis, Tipifarnib |
| Enrollment | 93 |
| Start date | Mar 24, 2004 |
| Primary completion | May 20, 2009 |
| Completion | Jul 5, 2017 |
| First posted | May 19, 2004 |
| Last update posted | Apr 13, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: